Loading
A phase 2 trial in lung cancer, run by Sun Yat-sen University, not yet recruiting.
Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC is a phase 2, randomised interventional study registered as NCT07294261 by Sun Yat-sen University, with a registry enrolment figure of 69 participants, started 2025-12-23 and due to reach its primary completion in 2028-10-30. Interventions recorded: Garsorasib, Benmelstobart, Anlotinib; Benmelstobart, Anlotinib; Garsorasib, Cetuximab Beta Injection. Conditions listed: Local Advanced or Metastatic NSCLC. Primary outcome: Overall response rate (ORR); DoR. Lung eligibility wording from the registry: "Histologically confirmed IIIB-IV NSCLC". Sites: China. No results are recorded here; the registry entry is the source.
Shares KRAS G12C-mutant non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares KRAS G12C-mutant non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares KRAS G12C-mutant non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares KRAS G12C-mutant non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.